DiaMedica Therapeutics Inc.
General ticker "DMAC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $223.9M (TTM average)
DiaMedica Therapeutics Inc. follows the US Stock Market performance with the rate: 51.7%.
Estimated limits based on current volatility of 5.3%: low 7.94$, high 8.83$
Factors to consider:
- Total employees count: 28 (+47.4%) as of 2024
- Top business risk factors: Operational and conduct risks, Completing clinical development, Regulatory and compliance, Strategic risks and growth management, Manufacturing scale up
- Current price 20.8% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.18$, 7.14$]
- 2025-12-31 to 2026-12-31 estimated range: [2.37$, 5.55$]
Financial Metrics affecting the DMAC estimates:
- Positive: with PPE of -8.9 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10.19 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 87.86 > 63.39
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 3.95 > -0.66
Short-term DMAC quotes
Long-term DMAC plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $14.00MM | $21.27MM | $26.68MM |
| Operating Income | $-14.00MM | $-21.27MM | $-26.68MM |
| Non-Operating Income | $0.35MM | $1.93MM | $2.27MM |
| R&D Expense | $7.84MM | $13.11MM | $19.06MM |
| Income(Loss) | $-13.65MM | $-19.34MM | $-24.41MM |
| Taxes | $0.03MM | $0.04MM | $0.03MM |
| Profit(Loss)* | $-13.68MM | $-19.38MM | $-24.44MM |
| Stockholders Equity | $31.83MM | $51.06MM | $40.72MM |
| Assets | $34.40MM | $54.16MM | $46.34MM |
| Operating Cash Flow | $-11.51MM | $-18.73MM | $-22.08MM |
| Capital expenditure | $0.08MM | $0.02MM | $0.03MM |
| Investing Cash Flow | $11.54MM | $-18.30MM | $8.56MM |
| Financing Cash Flow | $-0.01MM | $36.84MM | $11.99MM |
| Earnings Per Share** | $-0.52 | $-0.60 | $-0.60 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.